DNMT1 and malignant colon neoplasm: Goel et al. found that the suppression of the E2F-target DNMT1 triggers the expression of HERVs, IFN-III, and ISGs under CDK4/6-inhibitory drugs promoting anti-tumor immunity in colon cancer cells [77].